1. Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency
- Author
-
Aukrust P, Einar Martin Aandahl, Bs, Skålhegg, Nordøy I, Hansson V, Taskén K, Ss, Frøland, and Müller F
- Subjects
Adult ,CD4-Positive T-Lymphocytes ,Male ,CD3 Complex ,Cell-Free System ,Immune Sera ,T-Lymphocytes ,Immunology ,Drug Synergism ,Cell Separation ,CD8-Positive T-Lymphocytes ,Middle Aged ,Thionucleotides ,Lymphocyte Activation ,Cyclic AMP-Dependent Protein Kinases ,Enzyme Activation ,Common Variable Immunodeficiency ,Cyclic AMP ,Immunology and Allergy ,Humans ,Interleukin-2 ,Female ,Aged - Abstract
The molecular mechanisms underlying the T cell dysfunction often present in common variable immunodeficiency (CVI) are not established. cAMP-dependent protein kinase A type I (PKAI) is an important inhibitor of T cell proliferation after Ag stimulation. We therefore investigated the possibility that activation of PKAI may be involved in the development of T cell dysfunction in CVI. An exogenously added PKAI-selective antagonist (Rp-8-Br-cAMPS) induced a significant increase in anti-CD3-stimulated PBMC proliferation in 20 CVI patients compared with no effect in 15 controls. Purified T cells from 7 CVI patients with strictly defined T cell deficiency had elevated endogenous cAMP levels compared with controls. Treatment of T cells from these CVI patients with Rp-8-bromo-cAMP-phosphorothioate markedly improved anti-CD3-stimulated proliferation (up to 3.7-fold), particularly in CD4+ lymphocytes, reaching proliferation levels comparable to control values. No effect of cAMP antagonist on T cell proliferation was seen in controls. In these CVI patients, cAMP antagonist also increased IL-2 production in anti-CD3-stimulated T cells. However, exogenously added IL-2 at concentrations comparable to the achieved increase in IL-2 levels after addition of cAMP antagonist had no effect on T cell proliferation. Furthermore, the stimulatory effects of exogenously added IL-2 at higher concentrations and cAMP antagonist on T cell proliferation were additive. Our findings indicate that increased PKAI activation may be an important molecular basis for the T cell defect in CVI and suggest that the cAMP/PKAI system may be a potential molecular target for immunomodulating therapy in these patients.
- Published
- 1999